Kore Private Wealth’s Acadia Pharmaceuticals ACAD Stock Holding History

Kore Private Wealth’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-23	Closed	-$1K	–	280
2020 Q2	$1K	Hold	23	–	–	﹤0.01%	1071
2020 Q1	$1K	Hold	23	–	–	﹤0.01%	953
2019 Q4	$1K	Buy	+23	New	+$1K	﹤0.01%	960
2019 Q2	–	Sell	-46	Closed	-$1K	–	234
2019 Q1	$1K	Hold	46	–	–	﹤0.01%	871
2018 Q4	$1K	Buy	+46	New	+$893	﹤0.01%	826

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Kore Private Wealth's ACAD Position: Q3 2020 in Review

Kore Private Wealth sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 23 shares — an estimated $1K sold.

Kore Private Wealth first reported a position in ACAD in Q4 2018 and held it in 5 quarters. The position peaked at $1K in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Kore Private Wealth reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Kore Private Wealth sold 23 Acadia Pharmaceuticals shares in Q3 2020, an estimated $1K.
Kore Private Wealth first reported a position in Acadia Pharmaceuticals in Q4 2018 and held it in 5 quarters.
Kore Private Wealth's Acadia Pharmaceuticals position peaked at $1K in Q2 2020.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Kore Private Wealth's 13F filing for Q3 2020, filed 13 Nov 2020.